Ireland
News Category
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Cybin Raises US$175M in Registered Direct Offering to Advance Psychedelic-Based Mental Health Treatments
Cybin Inc. announced a US$175 million registered direct offering with warrants, signaling strong investor confidence in its late-stage clinical progra...
Cybin Schedules November 13 Call to Discuss Q2 Financial Results and Business Progress
Cybin Inc. will host a conference call and webcast on November 13, 2025, to review its second-quarter financial results and provide a business update,...
Hydromer Partners With Avem to Expand Access to Medical Coating Technologies Across Europe and the UK
Hydromer's partnership with Avem Market Solutions will provide European and UK medical device developers with enhanced access to advanced coating tech...
YouTube Tests In-App Video Sharing Feature, Resurrecting Private Messaging
YouTube is testing a new video-sharing and chat tool in Ireland and Poland, allowing users to share and discuss videos without leaving the app, which ...
Helus Pharma Closes $50 Million Public Offering to Advance Clinical Pipeline
Helus Pharma announced the closing of its $50 million public offering, with proceeds aimed at advancing Phase 3 and Phase 2 trials for depression and ...
Helus Pharma Surpasses 86% Enrollment in Phase 3 APPROACH Trial for Major Depressive Disorder
Helus Pharma announced that its Phase 3 APPROACH trial for HLP003, a novel serotonergic agonist for major depressive disorder, has surpassed 86% enrol...
Helus Pharma Prices $50 Million Public Offering to Advance Mental Health Treatments
Helus Pharma announced the pricing of a $50 million public offering to fund Phase 3 trials for its depression treatment HLP003 and other pipeline prog...
Exit Factor Targets International Expansion in 2026 Following Successful U.S. Growth
Exit Factor plans to enter New Zealand, Canada, Ireland, and the Netherlands with master franchisees and seek individual franchisees in Australia, bui...
Fully Promoted Reports Year-Over-Year Sales Growth and Global Expansion in 2025
Fully Promoted saw systemwide sales growth, added 57 new franchise agreements and 34 new locations in 2025, and expanded into India, Ireland, and Came...
Helus Pharma Appoints Michael Cola as CEO as It Advances Late-Stage Pipeline
Helus Pharma announced the appointment of Michael Cola as CEO, effective immediately, as the company prepares for key Phase 2 and Phase 3 data readout...
Helus Pharma Reports Q3 2025 Results, Advances Phase 3 and Phase 2 Programs
Helus Pharma reported Q3 2025 financial results and progress in its HLP003 Phase 3 trial for major depressive disorder and HLP004 Phase 2 trial for ge...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced that Phase 2a trial results for SPL026, published in Nature Medicine, showed significant reduction in depressive symptoms in ma...
Helus Pharma Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
Helus Pharma appointed Dr. Freda Lewis-Hall to its board and as chair of its Scientific Advisory Committee, bringing over 40 years of biopharmaceutica...
Helus Pharma Reports Positive Phase 2 Results for HLP004 in Generalized Anxiety Disorder
Helus Pharma announced positive topline Phase 2 results for HLP004, showing significant anxiety reduction in GAD patients with limited treatment optio...
First Data Center in Europe Using Microgrid Comes Online Near Dublin
Europe's first data center powered by a microgrid has launched in Ireland, offering a new solution to the energy demands of the digital economy by ope...
Helus Pharma Appoints Dr. Ken Kramer as SVP of Medical Affairs
Helus Pharma appoints Dr. Ken Kramer, a seasoned neuroscience executive, to lead medical affairs as the company advances its Phase 3 depression treatm...
Helus Pharma CEO Steps Down, Eric So Named Interim Chief Executive
Helus Pharma announced the immediate resignation of CEO Michael Cola and appointment of co-founder Eric So as interim CEO, ensuring continuity as the ...
Helus Pharma Enhances Scientific Advisory Board with Appointments of Dr. Robert Langer and Dr. Stephen Brannan
The addition of two renowned experts bolsters Helus Pharma's pipeline of novel serotonergic agonists for major depressive disorder and generalized anx...
Helus Pharma Issues Correction to TARA Mind Partnership Announcement, Reaffirms Alignment with Executive Order on Mental Health
Helus Pharma corrects its April 28, 2026 release regarding its partnership with TARA Mind, removing references to Veterans Exploring Treatment Solutio...
New Book Examines 1820 Debate That Shaped American Christianity
Craig Munro Wilson's 'Baptize America' reconstructs the 1820 Campbell-Walker debate as a pivotal moment in American religious history, arguing it set ...
Helus Pharma Chief Medical Officer to Present at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma announced that its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid ...